AWARDS

1.Prize awarded by German Society for Urology for poster: "Androgenrezeptormutation in einem fortgeschrittenen Prostatakarzinom: Charakterisierung des mutierten Rezeptors"; Wiesbaden, 1993.

 2.Travel award by Society for Basic Urological Research for poster: "Mutant androgen receptor in an advanced prostatic carcinoma is activated by adrenal androgens and progesterone"; Houston, 1993.

 3.Heinrich Warner prize for paper: "Androgen receptor activation in prostatic tumor cell lines   by insulin-like growth factor-I, keratinocyte growth factor and epidermal growth factor"; Hamburg, 1994.

4.Prize awarded by European Society for Urological Oncology and Endocrinology and   Society for Basic Urological Research for paper: "Induction of androgen receptor-mediated gene transcription in response to luteinizing hormone releasing hormone"; Rotterdam, 1995.

5.NIH travel award for poster „Agonistic action of bicalutamide (Casodex) in a new LNCaP subline obtained after long-term androgen ablation“; Bethesda, 1998.

6. CaP CURE research award for the proposal „Function of androgen receptor coactivators  and corepressors in advanced carcinoma of the prostate“; Santa Monica, 1998.

7. Dr Otto Seibert prize for promotion of science for work „Synergistic activation of androgen receptor by androgen and luteinizing hormone-releasing hormone in prostate carcinoma cells“; Innsbruck, 1999.

8. AUA best prostate cancer poster prize for work „Androgens, protein kinase A activators, 

and growth factors use different mechanisms to activate the androgen receptor“; Dallas,  1999.

9. Society for Basic Urological Research/Merck Young Investigator Award 2002., Orlando,     2002.

10. CaP Cure Award for project “Inhibition of CBP expression in prostate cancer in vivo”, Santa Monica, 2003.

11. European Association of Urology Award for the best paper in fundamental urological research: “Suppressor of cytokine signaling-3 antagonizes cAMP effects on proliferation and apoptosis and is expressed in human prostate cancer”, Berlin, 2007.

12. C. E. Alken Prize 2007 for paper: “Suppressor of cytokine signalling-3 is up-regulated by androgen in prostate cancer cell lines and inhibits androgen-mediated proliferation and secretion”, Heidelberg, 2008.

13. AUA lecture, Society for Basic Urological Research Atlanta 2010.

14. European Association of Urology Award Prostate Cancer for paper “Epithelial to mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205”, Stockholm 2014.

15. Dominique Chopin Distinguished Award European Section of Urological Research, Parma 2016.

 INVITED LECTURES:

1. 04.11.1994. Heinrich Warner Foundation, Hamburg: "Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor and epidermal growth factor"

2. 03.12.1994. Department of Urology, University of Graz: "Androgen receptor mutations in advanced prostate cancer"

3. 17.02.1995. Department of Urology, University of Munich: "Hormone resistance in prostate cancer“

4. 15.05.1995. Department of Urology, Charité, University of Berlin: "Androgen receptor in advanced prostate cancer: expression, structure and nonsteroidal activation"

5. 09.09.1995. Marbach Castle, Germany, symposium "Prostate, BPH, and prostate cancer": "Hormone resistance in prostate cancer"

6. 15.02.1996. Schering, Experimental Oncology, Berlin: "Androgen receptor activation by growth factors"

7. 30.03.1996. International Symposium on Biology of Prostate Growth, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Washington, DC, USA: "Activation of androgen receptor by growth factors"

8. 06.12.1996. French Association for Prostate Tumor Research, 6th Scientific Meeting, Paris, France: "Androgen receptor activation by growth factors"

9. 28.10.1997. Schering, Experimental Oncology, Berlin: „Androgen receptor down-regulation by growth factors and cytokines“

10. 07.11.1997. Department of Urology, University of Zagreb, Croatia: „The significance of androgen receptor point mutations for therapy of prostatic carcinoma“

11. 16.12.1997. Department of Urology Research, Mayo Clinic, Rochester, MN, USA: „Interaction of nonsteroidal antiandrogens with the wild-type and mutant androgen receptors“

12. 03.04.1998. Department of Cell Biology, Baylor College of Medicine, Houston, TX, USA: „Androgen receptor antisense oligonucleotides: why do we need them?“

13. 02.05.1998. 6th Cansteiner Colloquium, Biology of Normal and Abnormal Prostate Growth, Wolfsbrunnen Castle, Meinhard-Schwebda, Germany: Nuclear matrix proteins in biology of the normal and malignant prostate“

14. 28.04.1999. Departent of Urology, Northwestern University Medical School, Chicago, IL, USA: „New approaches for down-regulation of androgen receptor expression in prostate cancer“

15. 24.09.1999. Schering, Experimental Oncology, Berlin, Germany: „Inhibition of androgen receptor expression by basic fibroblast growth factor“

16. 04.10.1999. Laboratory for Experimental Endocrinology, Catholic University of Leuven, Belgium: „Androgen receptor alterations associated with long-term androgen deprivation in prostate cancer cells“

17. 14.10.1999. 6th Scientific Retreat CaP CURE, Incline Village, NV, USA: „Function of androgen receptor coactivators and corepressors in advanced carcinoma of the prostate“

18. 07.04.2000. British Columbia Cancer Research Centre, Department of Cancer Endocrinology, Vancouver, BC, Canada: „Interleukin-6: expression in prostate tissue and regulation of androgen receptor function“

19. 27.04.2000. Symposion „Molecular Mechanisms in Prostate Cancer“, Section of Urology, Medical College of Georgia, GA, USA: „Interleukin-6 and its receptor in prostate cancer: Regulation of androgen receptor activity and expression in tumor tissue“

20. 24.05.2000. Institute for Biomedical Research on Aging, Austrian Academy of Science, Innsbruck, Austria: „Regulation of prostate carcinoma: growth factors, interleukins and androgens“

21. 09.06.2000. Ljudevit Jurak Symposium in Comparative Pathology, Zagreb, Croatia: „Interleukin-6 and its receptor in prostate cancer: activation of androgen receptor and expression in prostate tissue“

22. 13.09.2000. Department of Urology, University of Berne, Switzerland: „Intermittent androgen withdrawal in vitro: expression and function of androgen receptor“

23. 14.09.2000. Annual Meeting of Swiss Urological Society, Interlaken, Switzerland: „Molecular biological aspects of prostate cancer“

24. 23.10.2000. Department of Urology, University of Zagreb, Croatia: „Importance of interleukin-6 for advanced carcinoma of the prostate“

25. 13.11.2000. Department of Urology Research, Mayo Clinic, Rochester, MN, USA: „Interleukin-6: regulator of androgen receptor activity and prostate cancer cell growth“

26. 20.11.2000. Schering, Experimental Oncology, Berlin, Germany: „CBP selectively enhances agonistic activity of hydroxyflutamide in prostate cancer cells“

27. 10.02.2001. 6th International Symposium on GnRH analogues in cancer and human reproduction, Geneva, Switzerland: „Androgen receptor-mediated growth of the malignant prostate“

28. 30.03.2001. Cancer Center, University of Virginia Health Science Center, Charlottesville, VA, USA: „Interleukin-6: regulator of androgen receptor activity and prostate cancer cell growth“

29. 07.04.2001. Congress of the European Association of Urology, Geneva, Switzerland: „Androgen receptor-mediated growth of benign and malignant prostate“

30. 31.08.2001. Symposium Comparative Clinical and Molecular Endocrinology, Urecht, The Netherlands: „Interleukin-6: regulator of androgen receptor activity and prostate cancer cell growth“

31. 19.11.2001. Nephrourological Meeting, University of Zagreb, Croatia: „Regulation of prostate growth by interleukin-6“

32. 30.11.2001. Fall Meeting of the Society for Basic Urological Research/4th World Congress in Urological Research, Tucson, AZ, USA: „Androgen receptor activation in prostate cancer by interleukin-6 family of cytokines“

33. 09.03.2002. AUA-EAU Exchange Programme, Innsbruck, Austria: „Molecular biology underlying the hormone resistance stage in prostate cancer“

34. 18.05.2002. Brain Trust Meeting The Role of the Prostate in Benign and Malignant Disease, Braselton, GA, USA: „Androgen receptor axis molecular endocrinology (AR signaling)“

35. 21.05.2002. The Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA: „Androgen receptor axis molecular endocrinology (AR Signaling)“

36. 23.05.2002. Department of Surgery, Division of Urology, Duke University Medical Center, Durham, NC, USA:Regulation of prostate cancer growth and androgen receptor activity by interleukin-6“

37. 20.09.2002. Conference Prostate 2002, Liverpool, United Kingdom: „Regulation of prostate cancer growth and androgen receptor activity by interleukin-6“

38. 10.10.2002. Progress and Controversies in Urological Oncology, Rotterdam, The Netherlands: „Basic research in prostate cancer: signal transduction“

39. 14.10.2002. 2nd International Conference on Prostate Cancer Research, Iowa City, IA, USA: „Interleukin-6 and related cytokines in prostate cancer progression“

40. 04.11.2002. Programm of Continuing Medical Education, University of Osijek, Croatia: „Role of steroid and petide hormones in regulation of the growth of prostate cancer“

41. 10.11.2002. Glaxo SmithKline Basic Science Prostate Symposium, Orlando, FL, USA: „Interleukin-6 activation of androgen receptor“

42. 10.12.2002. Hormone Club, University of Innsbruck, Austria: „Interleukin-6 in prostate cancer progression“

43. 07.03.2003. CNRS, University Blaise Pascal, Clermont-Ferrand, France: „Regulation of androgen receptor activity and prostate cancer growth by interleukin-6“

44. 25.06.2003. International Symposium on Hormonal Carcinogenesis, Valencia, Spain: “Interleukin-6 and androgen receptor in prostate cancer progression”

45. 29.08.2003. Reino Lahtikaari Symposium, Tampere, Finland: “Interleukin-6 regulation of growth of prostate cancers”

46. 29.01.2004. Department of Oncology, University of Cambridge, United Kingdom: “Interleukin-6: from a paracrine growth inhibitor to an autocrine growth stimulator in prostate cancer”

47. 06.03.2004. NIH Symposium on Androgen Action in Prostate Cancer, Keystone, CO, USA: “Regulation of expression and function of the androgen receptor coactivator CBP in prostate cancer”

48. 08.03.2004. Department of Urology, University of Michigan, Ann Arbor, MI, USA: “Direct and indirect effects of interleukin-6 in regulation of prostate cancer cell growth”

49. 11.05.2004. Endocrinology Grand Rounds University of Massachussets Medical School, Worcester, MA, USA: “Interleukin-6: direct and indirect effects on prostate cancer cell growth”

50. 17.05.2004. Department of Urology, University of Kentucky, Lexington, KY, USA: “Interleukin-6: translational research in prostate cancer”

51. 18.05.2004. Department of Biochemistry, University of Kentucky, Lexington, KY, USA: “Direct and indirect effects of interleukin-6 in regulation of prostate cancer proliferation and apoptosis”

52. 06.06.2004. Meeting of the Journal of Steroid Biochemistry and Molecular Biology, Seefeld, Austria: “Direct and indirect effects of interleukin-6 in regulation of androgen receptor activity and prostate cancer cell growth”

53. 28.06.2004. Department of Urology, University Hospital Charite, Berlin, Germany: “Regulation of androgen receptor activity and prostate cancer growth by interleukin-6”

54. 08.10.2004. Androgens 2004 Meeting, Berlin, Germany: “The androgen receptor coactivator CBP in development and progression of prostate carcinoma”

55. 22.10.2004. Annual Retreat Prostate Cancer Foundation, Incline Village, NV, USA: “The androgen receptor coactivator CBP in prostate carcinogenesis”

56. 05.11.2004. SBUR Satelite Symposium, Congress of the European Society for Urological Research, Athens, Greece: “Interleukin-6 regulation of prostate cancer cell growth, apoptosis, and androgen receptor activity”

57. 19.11.2004. AACR Special Conference “Basic, translational, and clinical advances in prostate cancer”, Bonita Springs, FL, USA: “The androgen receptor coactivator CBP and antagonist/agonist balance of androgen receptor blockers”

58. 28.01.2005. Network meeting, Breast, prostate, and endometrial cancer, Barcelona, Spain: “Interleukin-6 regulation of prostate cancer growth, apoptosis, and androgen receptor activity”

59. 02.06.2005. European School of Urology, Linz, Austria: “Cytokine involved in prostate cancer development and progression”

60. 22.06.2005. Northern Institute of Cancer Research, University of Newcastle, Newcastle, UK: “Interleukin-6: potential target for therapy in prostate cancer”

61. 17.09.2005. Meeting Interleukin-6: from molecular biology to therapy, Montpellier, France: “The role of interleukin-6 in prostate cancer”

62. 03.04.2006. European Congress of Endocrinology, Glasgow, UK: “Endocrine regulation of prostate growth”

63. 17.11.2006. Annual Meeting, Society for Basic Urological Research, Phoenix, AZ, USA: “Microenvironmental interleukins in prostate cancer progression”

64. 08.12.2006. Meeting on Diagnostic and Predictive Pathology, Palacky University, Olomouc, Czech Republic: “Interleukin-6 and suppressor of cytokine signaling-3 in regulation of proliferation and apoptosis in prostate cancer”

65. 13.03.3007. CNRS, Villejuif, France: “Interleukin-6 regulation of proliferation and apoptosis in prostate cancer: new directions for experimental therapy”

66. 26.04.2007. Department of Urology, University of Oslo, Norway: “Interleukin-6 and suppressors of cytokine signaling in regulation of prostate cancer cell proliferation and apoptosis”

67. 03.06.2007. Annual Meeting, American Society of Clinical Oncology, Chicago, IL, USA: “Androgen receptor coactivators in prostate cancer pathogenesis”

68. 07.06.2007. Kimmel Cancer Center, Jefferson University, Philadelphia, PA, USA: “Interleukin-6 and suppressor of cytokine signaling in regulation of prostate cancer cellular events”

69. 12.06.2007. Department of Cancer Biology and Cancer Center, University of Massachusetts Medical School, Worcester, MA, USA: “Interleukin-6 and suppressor of cytokine signaling-3 in regulation of prostate cancer cell proliferation and apoptosis”

70. 14.06.2007. Department of Urology, Mayo Clinic, Rochester, MN, USA:Control of proliferation and apoptosis in prostate cancer cells by interleukin-6 and suppressor of cytokine signaling-3”

71. 29.01.2008. Ludwig Boltzmann Institute for Cancer Research, Vienna, Austria:Interleukin-6 and suppressors of cytokine signaling in development and progression in prostate cancer”

72. 29.02.2008. Research Department, Hospital St. Gallen, Switzerland: “Interleukin-6, proliferation and apoptosis in prostate cancer”

73. 25.04.2008. Symposium & Workshop on Molecular Pathology, Olomouc, Czech Republic: “Androgen receptor coactivators CBP and p300 in prostate cancer development and progression”

74. 19.06.2008. Stanford University Cancer Center, Palo Alto, CA, USA: “Suppressors of cytokine signaling control multiple pathways in prostate cancer”

75. 15.09.2008. European Society for Therapeutic Radiology and Oncology Congress, Göteborg, Sweden: “Molecular determination of the clinical behaviour of prostate cancer. The molecular biologists´ point of view”

76. 29.11.2008. C.E.Alken Prize Winner Meeting, Heidelberg, Germany: “Suppressor of cytokine signalling-3 is up-regulated by androgen in prostate cancer cell lines and inhibits androgen-mediated proliferation and secretion”

77. 10.12.2008. University of Ulm, Germany: “Interleukin-6, proliferation and apoptosis in prostate cancer”

78. 10.06.2009. Department of Urology, Wayne State University, Detroit, MI, USA: “Contrasting role of suppressors of cytokine signaling in human prostate cancer”

79. 10.06.2009. Department of Pathology, Wayne State University, Detroit, MI, USA: “Contrasting role of suppressors of cytokine signaling in human prostate cancer”

80. 17.07.2009. Ludwig Boltzmann Institute for Cancer Research, Vienna, Austria: “Androgen receptor coactivators p300 and CBP in prostate cancer development and progression”

81. 07.12.2009. University of Strasbourg, France:Contrasting roles of interleukin-6 and suppressors of cytokine signalling in prostate cancer development and progression”

82. 12.11.2010. Society for Basic Urological Research, Atlanta, GA, USA: “Suppressors of cytokine signalling in controlling of inflammatory pathways and cellular events in prostate carcinoma”

83. 08.12.2010. University College Dublin, Ireland: “Control of pro-inflammatory cytokines in prostate cancer: unexpected role of suppressors of cytokine signalling”

84. 25.01.2011. Department of Urology, University of Ulm, Germany: “Pro-inflammatory cytokines in prostate cancer: clinical significance and signal transduction”

85. 07.04.2011. Kimmel Cancer Center, Jefferson University, Philadelphia, PA, USA: “Different effects of suppressors of cytokine signalling in prostate cancer depend on androgen sensitivity”

86. 28.04.2011. Lund University, Malmö, Sweden: “Effects of suppressors of cytokine signalling in prostate cancer depend on cellular context”

87. 13.05.2011. European School of Oncology, Lugano, Switzerland: “What is new and what is true in genitourinary oncology: tumor biology”

88. 25.02.2012. European Association of Urology, Annual Congress, Paris, France: “Future therapy in prostate cancer with siltuximab, an anti-IL-6 antibody”

89. 28.02.2012. Irish Cancer Society, Annual Meeting, Belfast, United Kingdom: “Cytokines in prostate cancer progression”

90. 09.04.2012. Cornell Medical Center, Rockefeller University, New York, NY, USA: “Complex action of suppressors of cytokine signalling and protein inhibitors of activated STAT in prostate cancer”

91. 09.04.2012. New York University Medical Center, New York, NY, USA: “Complex action of suppressors of cytokine signalling and protein inhibitors of activated STAT in prostate cancer”

92. 16.05.2012. Department of Pathology, University of Bonn, Germany: “Interleukin-6 in prostate cancer: diagnosis, signal transduction and experimental therapies”

93. 26.06.2012. Endocrine Society Annual Meeting, Houston, TX, USA: “Interleukin signalling in androgen receptor action”

94. 27.06.2012. Keck School of Medicine, Los Angeles, CA, USA: “Complex regulaton of cellular events in prostate cancer by suppressors of cytokine signalling and protein inhibitors of activated STAT”

95. 27.09.2012. German Society of Urology, Annual Congress, Leipzig, Germany: “Oncogene up-regulation during androgen ablation in prostate cancer: a hurdle for endocrine therapy”

96. 09.11.2012. Meeting Androgens 2012, Helsinki, Finland: “Interleukin-6, SOCS, and PIAS in androgen signalling”

97. 16.11.2012. Society for Basic Urological Research Annual Meeting, Miami Beach, FL, USA: “Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signalling pathways”

98. 15.03.2013. European Association of Urology Congress, Milan, Italy: “Distinguishing indolent from aggressive prostate cancer”

99. 15.04.2013. Retreat Ludwig Boltzman Institute for Cancer Research, Obergurgl, Austria: “Biological basis for anti-cytokine therapy in prostate cancer”

100. 17.01.2014. European Section for Urological Oncology, Prague, Czech Republic: “Biopsy and prostate cancer prognosis”

101. 25.04.2014. Molecular Pathology Days, Olomouc, Czech Republic: “Inhibitors of cytokine signalling in prostate cancer”

102. 08.05.2014. University of Oslo, Norway: “Suppressors of cytokine signalling in prostate cancer”

103. 26.05.2014. Department of Urology, University Hospital Salzburg, Austria: “The role of the androgen receptor in castration therapy-resistant prostate cancer”

104. 09.03.2015. Cancer Center, University of California Sacramento, CA; USA: “Interleukin-6 and endogenous inhibitors of cytokine signalling: lessons for improvement of therapy”

105. 05.08.2015. European School of Endocrinology, Bregenz, Austria: “Endocrine and hormone-dependent prostate cancer”

106. 15.01.2016. 12th Meeting of European Section of Oncologic Urology, Warsaw, Poland:

“Which markers are ready for clinical use”

107. 31.03.2016. Department of Urology, University of Tübingen, Germany: “Androgen receptor, metabolics and coactivators in prostate cancer”

108. 28.05.2016. D.A.Ch. Endocrinology Meeting, Munich, Germany: “Modulators of androgen action”

109. 08.10.2016. Central European Meeting, European Association of Urology, Vienna, Austria: “Basic science in urology: opportunities for collaboration in Central Europe”

110. 22.10.2016. European Section of Urological Research, Dominique Chopin Lecture, Parma, Italy: “Androgen receptor and cytokines: from bench to bedside”

111. 21.04.2017. Cancer Center, Medical College of Wisconsin, Milwaukee, WI, USA: “Cytokines, stemness, and chemotherapy resistance”

112. 17.11.2017. Norwegian University of Science and Technology, Trondheim, Norway: “Cytokines in endocrine- and chemotherapy resistance in castration therapy resistant prostate cancer”

113. 05.02.2018. Department of Urology, University of Mainz, Germany: “Cytokines and therapy resistance in prostate cancer”

114. 13.04.2018. Department of Pathology, University of Illinois at Chicago, IL, USA: “Regulation of androgen receptor activity in castration therapy-resistant prostate cancer by interleukins and coactivators”

115. 05.05.2018. Austrian Urology Association, Salzburg, Austria: “Genetic and therapy algorithms in prostate cancer”

116. 21.11.2018. ARTP Meeting (French Association for Prostate Cancer Research), Paris, France: “Inflammation and microbiota in prostate cancer”

  

© Robert Schober 2019